← Back to Search

Device

CCM Device for Heart Failure (INTEGRA-D Trial)

N/A
Recruiting
Led By Nir Uriel, MD
Research Sponsored by Impulse Dynamics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient is on GDMT for heart failure
Patient is aged 18 years or older
Must not have
End stage renal disease, currently on dialysis, or with other major medical disorder (e.g. liver failure, terminal cancer)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up implant to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to test if a device can safely and effectively treat ventricular fibrillation in people with Stage C or D heart failure.

Who is the study for?
This trial is for adults over 18 with heart failure (HFrEF) and a left ventricular ejection fraction (LVEF) of 40% or less, who are symptomatic despite treatment but don't qualify for cardiac resynchronization therapy. They must not be pregnant, have severe valve disease, unstable angina, other major medical conditions like end-stage renal disease, or be in another device/drug study.
What is being tested?
The OPTIMIZER® Integra CCM-D System is being tested to see if it can safely and effectively manage life-threatening rapid heartbeats in patients with advanced heart failure who aren't candidates for certain other therapies. The system will be implanted and monitored over at least two years.
What are the potential side effects?
Potential side effects may include complications from the implant procedure itself, inappropriate shocks from the device during follow-up period, and any issues related to having an electronic device within the body.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am on standard treatment for heart failure.
Select...
I am 18 years old or older.
Select...
My heart's pumping ability is reduced (LVEF ≤40%).
Select...
My heart failure is classified as Stage C or D.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a severe kidney disease, am on dialysis, or have a major illness like liver failure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~implant to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and implant to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Device Effectiveness in Converting Induced Ventricular Fibrillation (Primary Efficacy Objective)
Device-related Complications (Primary Safety Objective)
Secondary study objectives
Inappropriate Shock Rate out to 6-months (Secondary Safety Objective)
Other study objectives
Battery degradation and longevity
Charging non-compliance
Inappropriate Shock Rate out to 2-years
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CCM-D ImplantExperimental Treatment1 Intervention
The subject is implanted with the CCM-D device.

Find a Location

Who is running the clinical trial?

Impulse DynamicsLead Sponsor
13 Previous Clinical Trials
3,517 Total Patients Enrolled
Nir Uriel, MDPrincipal InvestigatorColumbia University
5 Previous Clinical Trials
288 Total Patients Enrolled
Niraj Varma, MD, PhDPrincipal InvestigatorThe Cleveland Clinic

Media Library

OPTIMIZER® Integra CCM-D System (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05855135 — N/A
Congestive Heart Failure Research Study Groups: CCM-D Implant
Congestive Heart Failure Clinical Trial 2023: OPTIMIZER® Integra CCM-D System Highlights & Side Effects. Trial Name: NCT05855135 — N/A
OPTIMIZER® Integra CCM-D System (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05855135 — N/A
~62 spots leftby Jun 2025